Disclosed herein is the use of an effective amount of an effective amount of a TOR kinase inhibitor represented by structural formula (I) and an effective amount of a cytidine analog in the manufacture of a medicament for treating or preventing cancer, particularly blood borne cancer which includes a lymphoma, a leukemia or a mutliple myeloma, wherein the variables shown in formula (I) are as defined in the specification.
